Latest Period
Q4 2025
Security Snapshot
ImageneBio, Inc. - Common Stock, $0.001 par value (IKNA) Institutional Ownership
CUSIP: 45175G108
13F Institutional Holders and Ownership History from Q1 2021 to Q4 2025
Institutions Reporting
0
Shares (Excl. Options)
0
Price
$1.43
- Type / Class
- Equity / Common Stock, $0.001 par value
- Symbol
- IKNA
- Shares outstanding
- 11,181,416
- Price per share
- $1.43
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 0
- Total reported value
- $0
- Share change
- -195,311
- Value change
- -$337,888
- Number of holders
- 0
- Price from insider filings
- $1.43
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- IKNA - ImageneBio, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 45175G108.
- 0 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 0 to 0 between Q3 2025 and Q4 2025.
- Reported value moved from $0 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Official SEC Source
Backed by Form 13F
Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.
See Original FilingInvestment Quick Answers
What is CUSIP 45175G108?
CUSIP 45175G108 identifies IKNA - ImageneBio, Inc. - Common Stock, $0.001 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Continue Investment Research
- Latest 13F filings for new institutional portfolio disclosures.
- Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
- Latest 10-Q/10-K reports to cross-check issuer fundamentals.
- Recent insider transactions for management buying/selling context.
- SEC investors directory and top value investors for manager-level discovery.
- All institutional ownership pages to compare adjacent CUSIP pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45175G108:
Significant Owners of ImageneBio, Inc. - Common Stock, $0.001 par value (IKNA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BML Investment Partners, L.P. | 8.5% | +11% | $4,335,508 | +$470,890 | 4,090,102 | +12% | Leonard Braden Michael | 16 Jun 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 8.3% | $4,246,958 | 4,006,564 | BVF PARTNERS L P/IL | 31 Dec 2024 | |||
| GILEAD SCIENCES, INC. | 3.6% | $1,612,591 | 1,521,312 | GILEAD SCIENCES INC | 31 Dec 2024 | |||
| ORBIMED ADVISORS LLC | 6.9% | -58% | $820,179 | -$7,669,269 | 773,754 | -90% | ORBIMED ADVISORS LLC | 25 Jul 2025 |
Institutional Holders of ImageneBio, Inc. - Common Stock, $0.001 par value (IKNA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$337,888 | $1.43 | 0 |
| 2025 Q3 | 0 | $0 | -$42,557,319 | $1.43 | 0 |
| 2025 Q2 | 31,761,826 | $42,558,064 | -$1,291,766 | $1.34 | 41 |
| 2025 Q1 | 32,747,670 | $41,911,271 | +$1,300,842 | $1.28 | 46 |
| 2024 Q4 | 31,710,905 | $52,000,859 | +$1,135,326 | $1.64 | 53 |
| 2024 Q3 | 28,407,567 | $49,141,929 | -$990,100 | $1.73 | 57 |
| 2024 Q2 | 29,008,434 | $47,863,122 | -$1,773,440 | $1.65 | 70 |
| 2024 Q1 | 30,097,815 | $42,738,427 | -$4,456,204 | $1.42 | 56 |
| 2023 Q4 | 32,386,521 | $63,800,942 | -$2,291,648 | $1.97 | 54 |
| 2023 Q3 | 32,711,624 | $141,562,445 | +$6,440,224 | $4.33 | 58 |
| 2023 Q2 | 31,199,169 | $204,665,347 | +$41,687,181 | $6.56 | 52 |
| 2023 Q1 | 24,986,737 | $86,204,879 | -$4,284,632 | $3.45 | 39 |
| 2022 Q4 | 26,264,313 | $69,861,906 | -$1,370,058 | $2.66 | 34 |
| 2022 Q3 | 26,245,163 | $93,168,465 | -$2,450,913 | $3.55 | 38 |
| 2022 Q2 | 26,785,272 | $118,660,000 | -$4,066,747 | $4.43 | 42 |
| 2022 Q1 | 27,489,815 | $167,777,122 | -$5,443,860 | $6.10 | 48 |
| 2021 Q4 | 27,390,236 | $343,559,318 | +$19,171,509 | $12.54 | 48 |
| 2021 Q3 | 19,762,442 | $249,413,000 | -$3,111,777 | $12.62 | 37 |
| 2021 Q2 | 21,064,974 | $293,196,000 | +$21,248,510 | $14.04 | 42 |
| 2021 Q1 | 19,313,430 | $538,519,000 | +$538,519,000 | $28.25 | 27 |